On March 9, Hengrui Medicine (600276/01276) issued an announcement stating that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" for HRS9531 injection issued by the National Medical Products Administration, and will conduct clinical trials in the near future.

The application for this drug was for clinical trials, with application numbers CXHL2501355 and CXHL2501356. The approval conclusion indicated that the application met the relevant requirements for drug registration and approved the commencement of clinical trials for chronic kidney disease. HRS9531 injection is a globally proprietary intellectual property.This novel dual agonist targeting both gastric inhibitory peptide receptor and glucagon-like peptide-1 receptor has the effects of regulating glucose and lipid metabolism, suppressing appetite, and enhancing insulin sensitivity.

To date, the cumulative R&D investment in HRS9531-related projects is approximately RMB 632 million (unaudited). The company reminds investors that the drug development and market launch process is lengthy and subject to uncertainties.

In the first three quarters of 2025, Hengrui Medicine achieved revenue of RMB 23.188 billion and net profit attributable to the parent company of RMB 5.751 billion.

https://finance.eastmoney.com/a/202603093666164556.html